{"entity":{"id":"nct05984485","kind":"trial","name":"The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Ca","aka":["TaLaR-02"],"tldr":"A phase 3 trial in colorectal cancer, run by Sun Yat-sen University, now recruiting.","summary":"The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer is a phase 3, randomised interventional study registered as NCT05984485 by Sun Yat-sen University, with a registry enrolment figure of 766 participants, started 2022-07-05 and due to reach its primary completion in 2028-07. Interventions recorded: neoadjuvant chemotherapy plus total mesorectal excision; total mesorectal excision. Conditions listed: Rectal Cancer. Primary outcome: 3-year Disease Free Survival. Colorectal eligibility wording from the registry: \"Pathologically confirmed rectal adenocarcinoma;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05984485","url":"https://clinicaltrials.gov/study/NCT05984485"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05984485","phase":"3","setting":"TME vs TME+nCT in Low-risk LARC","sponsor":"Sun Yat-sen University","enrolled":766,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05984485/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}